{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:42:37Z","timestamp":1792190557634,"version":"4.4.0"},"reference-count":34,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T00:00:00Z","timestamp":1700179200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Evidence suggests that patients with Hashimoto thyroiditis (HT) are at significantly higher risk of developing papillary thyroid cancer (PTC). However, the course of PTC in patients with both diseases concomitantly has been found to be more indolent than conventional PTC. Additionally, it has been well proven that BRAF mutation results in an aggressive course of PTC. The aims of this meta-analysis were to identify prevalence of BRAF mutation and its impact on clinicopathological features in patients with concomitant PTC-HT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Medline, Cochrane Library, Scopus, and Web of Science were searched until 16.09.2022, resulting in 227 articles, of which nine studies were included. Summary estimates, comparing patients with (A) BRAF (+) PTC-HT versus BRAF (+) PTC, and (B) BRAF (+) PTC-HT versus BRAF (-) PTC-HT, were generated with Review Manager 5.0.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>In total, 6395 patients were included in this review. PTC-HT patients had significantly less BRAF mutation than PTC patients (Odds Ratio (OR) (95% Confidence Interval (CI))=0.45 (0.35-0.58), P&amp;lt;0.001). BRAF (+) PTC-HT patients were significantly more likely to have multifocal lesions (OR (95% CI)=1.22 (1.04-1.44), P=0.01) but less likely to have lymph node metastasis (OR (95% CI)=0.65 (0.46-0.91), P=0.01) and extrathyroidal extension (OR (95% CI)=0.55 (0.32-0.96), P=0.03) compared to BRAF (+) PTC patients. BRAF (+) PTC-HT patients were more likely to have multifocal lesions (OR (95% CI)=0.71 (0.53-0.95), P=0.02), lymph node metastasis (OR (95% CI)=0.59 (0.44-0.78), P&amp;lt;0.001) and extrathyroidal extension (OR (95% CI)=0.72 (0.56-0.92), P=0.01) compared to BRAF (-) PTC-HT patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This meta-analysis highlights that the lower prevalence of BRAF mutation in patients with PTC-HT than conventional PTC may explain the indolent clinicopathological course in this cohort.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2023.1273498","type":"journal-article","created":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:05:38Z","timestamp":1700283938000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":18,"title":["Prevalence and Impact of BRAF mutation in patients with concomitant papillary thyroid carcinoma and Hashimoto\u2019s thyroiditis: a systematic review with meta-analysis"],"prefix":"10.3389","volume":"14","author":[{"given":"Lukasz","family":"Janicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agastya","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaros\u0142aw","family":"Jendrzejewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Hellmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,11,17]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1155\/2013\/965212","article-title":"Worldwide increasing incidence of thyroid cancer: Update on epidemiology and risk factors","volume":"2013","author":"Pellegriti","year":"2013","journal-title":"J Cancer Epidemiol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.28054","article-title":"Hashimoto\u2019s thyroiditis effects on papillary thyroid carcinoma outcomes: A systematic review","volume":"14","author":"Osborne","year":"2022","journal-title":"Cureus"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.32448\/entupdates.711666","article-title":"Assessment of BRAF-V600E, KRAS, NRAS and EGFR mutations in papillary thyroid carcinoma and Hashimoto\u2019s thyroiditis","volume":"10","author":"Ozdamar","year":"2020","journal-title":"ENT UPDATES"},{"key":"B4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s40463-017-0247-6","article-title":"Clinical implications of the BRAF mutation in papillary thyroid carcinoma and chronic lymphocytic thyroiditis","volume":"47","author":"Kim","year":"2018","journal-title":"J Of Otolaryngology-Head \\& Neck Surg"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2018.33.4.473","article-title":"Associations between Hashimoto thyroiditis and clinical outcomes of papillary thyroid cancer: A meta-analysis of observational studies","volume":"33","author":"Moon","year":"2018","journal-title":"Endocrinol Metab"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1677\/ERC-09-0036","article-title":"Lower levels of TSH are associated with a lower risk of papillary thyroid cancer in patients with thyroid nodular disease: Thyroid autonomy may play a protective role","volume":"16","author":"Fiore","year":"2009","journal-title":"Endocrine-Related Cancer"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-014-1629-z","article-title":"The study of the coexistence of Hashimoto\u2019s thyroiditis with papillary thyroid carcinoma","volume":"140","author":"Zhang","year":"2014","journal-title":"J Of Cancer Res And Clin Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-12-0903","article-title":"The association between papillary thyroid carcinoma and histologically proven Hashimoto\u2019s thyroiditis: A meta-analysis","volume":"168","author":"Lee","year":"2013","journal-title":"Eur J Endocrinol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1177\/0194599812445727","article-title":"Role of chronic lymphocytic thyroiditis in central node metastasis of papillary thyroid carcinoma","volume":"147","author":"Paulson","year":"2012","journal-title":"OTOLARYNGOLOGY-HEAD AND Neck Surg"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.801925","article-title":"Hashimoto\u2019s thyroiditis: A ``Double-edged sword{\u2018\u2018} in thyroid carcinoma","volume":"13","author":"Xu","year":"2022","journal-title":"Front IN Endocrinol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1827.2005.01866.x","article-title":"Mutations of the BRAF gene in papillary thyroid carcinoma and in Hashimoto\u2019s thyroiditis","volume":"55","author":"Kim","year":"2005","journal-title":"Pathol Int"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1210\/er.2007-0007","article-title":"BRAF mutation in papillary thyroid cancer: Pathogenic role, molecular bases, and clinical implications","volume":"28","author":"Xing","year":"2007","journal-title":"Endocrine Rev"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/JC.2005-0987","article-title":"BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer","volume":"90","author":"Xing","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2013.3190","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","journal-title":"JAMA"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1111\/cen.12194","article-title":"BRAF mutation positive papillary thyroid carcinoma is less advanced when Hashimoto\u2019s thyroiditis lymphocytic infiltration is present","volume":"79","author":"Marotta","year":"2013","journal-title":"Clin Endocrinol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1530\/ERC-15-0408","article-title":"Chronic lymphocytic thyroiditis and BRAF V600E in papillary thyroid carcinoma","volume":"23","author":"Kim","year":"2016","journal-title":"ENDOCRINE-RELATED Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/biomedicines10082051","article-title":"Hashimoto\u2019s thyroiditis minimizes lymph node metastasis in BRAF mutant papillary thyroid carcinomas","volume":"10","author":"Issa","year":"2022","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2008.0144","article-title":"Clinical and pathological features and the BRAFV600E mutation in patients with papillary thyroid carcinoma with and without concurrent Hashimoto thyroiditis","volume":"19","author":"Kim","year":"2009","journal-title":"Thyroid"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/hed.24149","article-title":"Potential relationship between Hashimoto\u2019s thyroiditis and BRAFV600E mutation status in papillary thyroid cancer","volume":"36","author":"Zeng","year":"2016","journal-title":"Head Neck"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/hed.23854","article-title":"Combined effect of Hashimoto\u2019s thyroiditis and BRAFV600E mutation status on aggressiveness in papillary thyroid cancer Su-jin","volume":"38","author":"Kim","year":"2016","journal-title":"Head Neck"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0269995","article-title":"Association between Hashimoto thyroiditis and clinical outcomes of papillary thyroid carcinoma: A meta-analysis","volume":"17","author":"Tang","year":"2022","journal-title":"PloS One"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/9959649","article-title":"Risk and prognostic factors for BRAFV600EMutations in papillary thyroid carcinoma","volume":"2022","author":"Wei","year":"2022","journal-title":"BioMed Res Int"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1677\/erc.1.01086","article-title":"Correlation between B-RAFV600E mutation and clinico-pathologic parameters in papillary thyroid carcinoma: Data from a multicentric Italian study and review of the literature","volume":"13","author":"Fugazzola","year":"2006","journal-title":"Endocrine-Related Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1677\/ERC-07-0212","article-title":"BRAF(V600E) mutation and the biology of papillary thyroid cancer","volume":"15","author":"Frasca","year":"2008","journal-title":"Endocrine-Related Cancer"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.2741\/4359","article-title":"The role of BRAF in the pathogenesis of thyroid carcinoma","volume":"20","author":"Li","year":"2015","journal-title":"Front Bioscience - Landmark"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-06-0739","article-title":"Conditional Activation of RET\/PTC3 and BRAFV600E in thyroid cells is associated with gene expression profiles that predict a preferential role of BRAF in extracellular matrix remodeling","volume":"66","author":"Mesa","year":"2006","journal-title":"Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-013-1397-1","article-title":"Follicular epithelial dysplasia of the thyroid: morphological and immunohistochemical characterization of a putative preneoplastic lesion to papillary thyroid carcinoma in chronic lymphocytic thyroiditis","volume":"462","author":"Chui","year":"2013","journal-title":"VIRCHOWS ARCHIV"},{"key":"B28","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1177\/0194599812472426","article-title":"Hashimoto\u2019s thyroiditis as a risk factor of papillary thyroid cancer may improve cancer prognosis","volume":"148","author":"Lun","year":"2013","journal-title":"Otolaryngol - Head Neck Surg (United States)"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2014.09.001","article-title":"Hashimoto\u2019s thyroiditis and papillary thyroid cancer: are they immunologically linked","volume":"25","author":"Ehlers","year":"2014","journal-title":"Trends IN Endocrinol AND Metab"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2006.0306","article-title":"Lymphocyte and immature dendritic cell infiltrates in differentiated, poorly differentiated, and undifferentiated thyroid carcinoma","volume":"17","author":"Ugolini","year":"2007","journal-title":"Thyroid"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.surg.2013.07.021","article-title":"The relationship between chronic lymphocytic thyroiditis and central neck lymph node metastasis in North American patients with papillary thyroid carcinoma","volume":"154","author":"Jara","year":"2013","journal-title":"SURGERY"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jss.2012.09.017","article-title":"Is thyroidectomy in patients with Hashimoto thyroiditis more risky","volume":"178","author":"McManus","year":"2012","journal-title":"J Surg Res"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.7326\/M18-0284","article-title":"Thyroidectomy versus medical management for euthyroid patients with hashimoto disease and persisting symptoms: A randomized trial","volume":"170","author":"Guldvog","year":"2019","journal-title":"Ann Internal Med"},{"key":"B34","doi-asserted-by":"publisher","first-page":"799","DOI":"10.5603\/EP.A2022.0087","article-title":"Diagnosis and treatment of thyroid cancer in adult patients - Recommendations of Polish Scientific Societies and the National Oncological Strategy. Update of the 2022 Update [Diagnostyka i leczenie raka tarczycy u chorych doros\u0142ych - Rekomendacje Polskich","volume":"73","author":"Krajewska","year":"2022","journal-title":"Endokrynologia Polska"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1273498\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,18]],"date-time":"2023-11-18T05:05:41Z","timestamp":1700283941000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2023.1273498\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,17]]},"references-count":34,"alternative-id":["10.3389\/fendo.2023.1273498"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2023.1273498","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,17]]},"article-number":"1273498"}}